WHO issues alert on the use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy: Geneva Saturday, June 28, 2025, 11:00 Hrs [IST] WHO is alerting ...

Geneva: The World Health Organization (WHO) has issued a global safety alert highlighting the risk of non-arteritic anterior ...

June 6 (Reuters) - Novo Nordisk's (NOVOb.CO) popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases ...

Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking ...

Following a review of all available data, the EMA's Pharmacovigilance Risk Assessment Committee determined that semaglutide increases the risk for non-arteritic anterior ischemic optic neuropathy ...

Nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss, is a “very rare” side effect of treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, ...

The deep learning system distinguishes IIH, NAION, and healthy eyes with 93.6% accuracy, aiding in resource-limited settings.

The European Medicines Agency (EMA) has warned that popular weight-loss and diabetes drugs containing semaglutide — including ...